These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27365387)

  • 1. Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence.
    Gupta SB; Mehta V; Dubberke ER; Zhao X; Dorr MB; Guris D; Molrine D; Leney M; Miller M; Dupin M; Mast TC
    Clin Infect Dis; 2016 Sep; 63(6):730-734. PubMed ID: 27365387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection.
    Villafuerte Gálvez JA; Kelly CP
    Expert Rev Gastroenterol Hepatol; 2017 Jul; 11(7):611-622. PubMed ID: 28636484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).
    Leav BA; Blair B; Leney M; Knauber M; Reilly C; Lowy I; Gerding DN; Kelly CP; Katchar K; Baxter R; Ambrosino D; Molrine D
    Vaccine; 2010 Jan; 28(4):965-9. PubMed ID: 19941990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
    Gerding DN; Kelly CP; Rahav G; Lee C; Dubberke ER; Kumar PN; Yacyshyn B; Kao D; Eves K; Ellison MC; Hanson ME; Guris D; Dorr MB
    Clin Infect Dis; 2018 Aug; 67(5):649-656. PubMed ID: 29538686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a new serological assay for the diagnosis of Clostridium difficile infections with prognostic value.
    von Bechtolsheim F; Varga A; Szereday L; Polgar B; Balassa T; Kocsis B; Peterfi Z; Miko E
    J Microbiol Methods; 2019 Dec; 167():105777. PubMed ID: 31733265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.
    Yang Z; Ramsey J; Hamza T; Zhang Y; Li S; Yfantis HG; Lee D; Hernandez LD; Seghezzi W; Furneisen JM; Davis NM; Therien AG; Feng H
    Infect Immun; 2015 Feb; 83(2):822-31. PubMed ID: 25486992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-toxin antibody is not associated with recurrent Clostridium difficile infection.
    Gilbert J; Leslie J; Putler R; Weiner S; Standke A; Penkevich A; Keidan M; Young VB; Rao K
    Anaerobe; 2021 Feb; 67():102299. PubMed ID: 33227427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitive assays enable detection of serum IgG antibodies against Clostridium difficile toxin A and toxin B in healthy subjects and patients with Clostridium difficile infection.
    Zhao X; Bender F; Shukla R; Kang JJ; Caro-Aguilar I; Laterza OF
    Bioanalysis; 2016 Apr; 8(7):611-23. PubMed ID: 26964649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single nucleotide polymorphisms of the tcdC gene and presence of the binary toxin gene predict recurrent episodes of Clostridium difficile infection.
    Stewart DB; Berg AS; Hegarty JP
    Ann Surg; 2014 Aug; 260(2):299-304. PubMed ID: 24374512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of antitoxin responses in Clostridium-difficile-infected patients compared to healthy blood donors.
    von Eichel-Streiber A; Paik W; Knight K; Gisch K; Nadjafi K; Decker C; Bosnjak O; Cheknis A; Johnson S; von Eichel-Streiber C
    Anaerobe; 2016 Oct; 41():91-103. PubMed ID: 27427464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.
    Bouza E; Cornely OA; Ramos-Martinez A; Plesniak R; Ellison MC; Hanson ME; Dorr MB
    Eur J Clin Microbiol Infect Dis; 2020 Oct; 39(10):1933-1939. PubMed ID: 32504314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic-associated diarrhea.
    Bacon AE; Fekety R
    Diagn Microbiol Infect Dis; 1994 Apr; 18(4):205-9. PubMed ID: 7924215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters.
    Babcock GJ; Broering TJ; Hernandez HJ; Mandell RB; Donahue K; Boatright N; Stack AM; Lowy I; Graziano R; Molrine D; Ambrosino DM; Thomas WD
    Infect Immun; 2006 Nov; 74(11):6339-47. PubMed ID: 16966409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Healthcare Burden of Multiple Recurrences of Clostridium difficile Infection.
    Sheitoyan-Pesant C; Abou Chakra CN; Pépin J; Marcil-Héguy A; Nault V; Valiquette L
    Clin Infect Dis; 2016 Mar; 62(5):574-580. PubMed ID: 26582748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in the Elderly: Long-Term Outcomes and Microbiota Changes.
    Girotra M; Garg S; Anand R; Song Y; Dutta SK
    Dig Dis Sci; 2016 Oct; 61(10):3007-3015. PubMed ID: 27447476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea.
    Kyne L; Warny M; Qamar A; Kelly CP
    Lancet; 2001 Jan; 357(9251):189-93. PubMed ID: 11213096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
    Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
    Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.
    Kyne L; Warny M; Qamar A; Kelly CP
    N Engl J Med; 2000 Feb; 342(6):390-7. PubMed ID: 10666429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum antibody responses to Clostridium difficile toxin A: predictive and protective?
    Phillips C
    Gut; 2001 Aug; 49(2):167-8. PubMed ID: 11454789
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of the premier toxin A and B assay and the TOX A/B II assay for diagnosis of Clostridium difficile infection.
    Novak-Weekley SM; Hollingsworth MH
    Clin Vaccine Immunol; 2008 Mar; 15(3):575-8. PubMed ID: 18175802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.